NLS Pharmaceutics Terminates Nolazol License with Eurofarma
Ticker: NCEL · Form: 6-K · Filed: Sep 13, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Sep 13, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: licensing-agreement, termination, drug-development
TL;DR
NLS Pharma terminates Nolazol deal with Eurofarma, taking back Latin America rights.
AI Summary
NLS Pharmaceutics Ltd. announced on September 13, 2024, the termination of its February 2019 license agreement with Eurofarma Laboriatorios S.A. (Eurofarma). This agreement granted Eurofarma rights to develop and commercialize NLS's product candidate, Nolazol, in Latin American countries.
Why It Matters
The termination of this agreement means NLS Pharmaceutics will regain full control over the development and commercialization of Nolazol in Latin America, potentially impacting future revenue streams and strategic partnerships.
Risk Assessment
Risk Level: medium — The termination of a key licensing agreement can indicate challenges in product development, commercialization strategy, or partner relationships, introducing uncertainty for the company's future prospects.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- Eurofarma Laboriatorios S.A. (company) — Licensee
- Nolazol (product) — Product candidate
- February 2019 (date) — Date of original agreement
- September 13, 2024 (date) — Date of termination announcement
FAQ
What is the primary reason for the termination of the Eurofarma license agreement?
The filing does not specify the reason for the termination, only that the agreement has been terminated.
What product candidate was covered by the Eurofarma license agreement?
The product candidate covered was Nolazol.
In which geographical region did Eurofarma have rights to commercialize Nolazol?
Eurofarma had rights to commercialize Nolazol in Latin American countries.
When was the original license agreement with Eurofarma entered into?
The original license agreement was entered into in February 2019.
Does the filing indicate if NLS Pharmaceutics plans to find a new partner for Nolazol in Latin America?
The filing does not provide information on NLS Pharmaceutics' future plans for the Latin American market regarding Nolazol.
Filing Stats: 431 words · 2 min read · ~1 pages · Grade level 13.7 · Accepted 2024-09-13 17:01:15
Filing Documents
- ea0213701-6k_nlspharma.htm (6-K) — 13KB
- ea021370101ex99-1_nlspharma.htm (EX-99.1) — 182KB
- ex99-1_001.jpg (GRAPHIC) — 1KB
- ex99-1_002.jpg (GRAPHIC) — 12KB
- ex99-1_003.jpg (GRAPHIC) — 3KB
- 0001213900-24-078645.txt ( ) — 218KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: September 13, 2024 By: /s/ Alexander C. Zwyer Name: Alexander C. Zwyer Title: Chief Executive Officer 3